Evidence map›Paper›PMID 28973395›Full record

ArticleHuman molecular genetics2017

TUBB4A mutations result in specific neuronal and oligodendrocytic defects that closely match clinically distinct phenotypes.

Julian Curiel, Guillermo Rodríguez Bey, Asako Takanohashi, Marianna Bugiani, Xiaoqin Fu, Nicole I Wolf, Bruce Nmezi, Raphael Schiffmann, Mona Bugaighis, Tyler Pierson and 6 more

Open access · bronzeAbstract read
In one paragraph

Article in Human molecular genetics, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 50 papers.

0numbers the graph read from it
0cells of the map it votes in
50citing papers in PubMed
2.8field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

50 citing papers in PubMed, 86 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Genotypic and phenotypic heterogeneity in tubulinopathies: insights from a Turkish multicenter cohort.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2026
    Article
  5. Complicated Spastic Paraparesis: Study of a Patient With a De Novo Pathogenic Variant in ELOVL1.International journal of developmental neuroscience : the official journal of the International Society for Developmental Neuroscience · 2026
    Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Divergent somatic mutation patterns among human cerebellar neuron types.bioRxiv : the preprint server for biology · 2025
    Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 6 institutions in 3 countries.

Julian CurielCenter for Neuroscience Research, Children's National Health System, Children's Research Institute, Washington, DC 20010, USA.
Guillermo Rodríguez BeyDepartment of Human Genetics, University of Pittsburgh, Pittsburgh, PA 15260, USA.
Asako TakanohashiCenter for Genetic Medicine Research, Children's National Health System, Children's Research Institute, Washington, DC 20010, USA.
Marianna BugianiVU University Medical Center, Amsterdam, The Netherlands.
Xiaoqin FuCenter for Neuroscience Research, Children's National Health System, Children's Research Institute, Washington, DC 20010, USA.
Nicole I WolfVU University Medical Center, Amsterdam, The Netherlands.
Bruce NmeziDepartment of Human Genetics, University of Pittsburgh, Pittsburgh, PA 15260, USA.
Raphael SchiffmannInstitute of Metabolic Disease, Baylor Scott & White Research Institute, Dallas, TX 75204, USA.
Mona BugaighisCenter for Neuroscience Research, Children's National Health System, Children's Research Institute, Washington, DC 20010, USA.
Tyler PiersonDepartments of Pediatrics and Neurology, Cedar Sinai Medical Center, Board of Governors Regenerative Medicine Institute, Los Angeles, CA 90048, USA.
Guy HelmanCenter for Genetic Medicine Research, Children's National Health System, Children's Research Institute, Washington, DC 20010, USA.
Cas SimonsInstitute for Molecular Bioscience, University of Queensland, Brisbane, Australia.
Marjo S van der KnaapVU University Medical Center, Amsterdam, The Netherlands.
Judy LiuCenter for Neuroscience Research, Children's National Health System, Children's Research Institute, Washington, DC 20010, USA.
Quasar PadiathDepartment of Human Genetics, University of Pittsburgh, Pittsburgh, PA 15260, USA.
Adeline VanderverCenter for Genetic Medicine Research, Children's National Health System, Children's Research Institute, Washington, DC 20010, USA.
Children's National · USAmsterdam UMC Location Vrije Universiteit Amsterdam · NLUniversity of Pittsburgh · USChildren's Hospital of Philadelphia · USBaylor Medical Center at Garland · USThe University of Queensland · AU

Funding

Elucidating mechanisms involved in Lamin B1 mediated demyelinationR01NS095884 · NINDS · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI PADIATH, QUASAR S · 2016 to 2020
$2.1M
NINDS NIH HHS R01 NS095884
6 · The paper itself

Abstract

Hypomyelinating leukodystrophies are heritable disorders defined by lack of development of brain myelin, but the cellular mechanisms of hypomyelination are often poorly understood. Mutations in TUBB4A, encoding the tubulin isoform tubulin beta class IVA (Tubb4a), result in the symptom complex of hypomyelination with atrophy of basal ganglia and cerebellum (H-ABC). Additionally, TUBB4A mutations are known to result in a broad phenotypic spectrum, ranging from primary dystonia (DYT4), isolated hypomyelination with spastic quadriplegia, and an infantile onset encephalopathy, suggesting multiple cell types may be involved. We present a study of the cellular effects of TUBB4A mutations responsible for H-ABC (p.Asp249Asn), DYT4 (p.Arg2Gly), a severe combined phenotype with hypomyelination and encephalopathy (p.Asn414Lys), as well as milder phenotypes causing isolated hypomyelination (p.Val255Ile and p.Arg282Pro). We used a combination of histopathological, biochemical and cellular approaches to determine how these different mutations may have variable cellular effects in neurons and/or oligodendrocytes. Our results demonstrate that specific mutations lead to either purely neuronal, combined neuronal and oligodendrocytic or purely oligodendrocytic defects that closely match their respective clinical phenotypes. Thus, the DYT4 mutation that leads to phenotypes attributable to neuronal dysfunction results in altered neuronal morphology, but with unchanged tubulin quantity and polymerization, with normal oligodendrocyte morphology and myelin gene expression. Conversely, mutations associated with isolated hypomyelination (p.Val255Ile and p.Arg282Pro) and the severe combined phenotype (p.Asn414Lys) resulted in normal neuronal morphology but were associated with altered oligodendrocyte morphology, myelin gene expression, and microtubule dysfunction. The H-ABC mutation (p.Asp249Asn) that exhibits a combined neuronal and myelin phenotype had overlapping cellular defects involving both neuronal and oligodendrocyte cell types in vitro. Only mutations causing hypomyelination phenotypes showed altered microtubule dynamics and acted through a dominant toxic gain of function mechanism. The DYT4 mutation had no impact on microtubule dynamics suggesting a distinct mechanism of action. In summary, the different clinical phenotypes associated with TUBB4A reflect the selective and specific cellular effects of the causative mutations. Cellular specificity of disease pathogenesis is relevant to developing targeted treatments for this disabling condition.

Indexed as

AdolescentAdultAtrophyBasal GangliaBrainCataractCerebellumChildChild, PreschoolFemaleHeLa CellsHereditary Central Nervous System Demyelinating DiseasesHumansLeukodystrophy, MetachromaticMagnetic Resonance ImagingMaleTUBB4A protein, humanTubulin

Identifiers

PMID28973395
PMCPMC7462055
OpenAlexW2752005215

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.